696 related articles for article (PubMed ID: 32421194)
1. Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study.
Valerio H; Alavi M; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Dore GJ; Grebely J
Clin Infect Dis; 2021 Jul; 73(1):e69-e78. PubMed ID: 32421194
[TBL] [Abstract][Full Text] [Related]
2. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.
Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J;
Int J Drug Policy; 2022 Jul; 105():103706. PubMed ID: 35533635
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the prevalence of current hepatitis C infection and treatment among Aboriginal and Torres Strait Islander peoples who inject drugs in Australia: The ETHOS engage study.
Hobday S; Valerio H; Combo T; Monaghan R; Scott C; Silk D; Murray C; Read P; Henderson C; Degenhardt L; Treloar C; Dore GJ; Grebely J; Martinello M;
Drug Alcohol Rev; 2023 Nov; 42(7):1617-1632. PubMed ID: 37556376
[TBL] [Abstract][Full Text] [Related]
4. Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study.
Valerio H; Conway A; Alavi M; Treloar C; Silk D; Murray C; Henderson C; Amin J; Read P; Degenhardt L; Christmass M; Montebello M; Dore GJ; Grebely J;
Int J Drug Policy; 2022 Dec; 110():103876. PubMed ID: 36240657
[TBL] [Abstract][Full Text] [Related]
5. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy.
Iversen J; Dore GJ; Starr M; Catlett B; Cunningham P; Geddes L; Maher L
Int J Drug Policy; 2020 Sep; 83():102837. PubMed ID: 32645585
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with hepatitis C testing, treatment, and current hepatitis C infection among men and women who inject drugs: The ETHOS engage study.
Valerio H; Marshall AD; Conway A; Treloar C; Carter L; Martinello M; Henderson C; Amin J; Read P; Silk D; Degenhardt L; Prain B; Alavi M; Dore GJ; Grebely J;
Int J Drug Policy; 2024 May; 127():104394. PubMed ID: 38608357
[TBL] [Abstract][Full Text] [Related]
7. Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis.
Grebely J; Tran L; Degenhardt L; Dowell-Day A; Santo T; Larney S; Hickman M; Vickerman P; French C; Butler K; Gibbs D; Valerio H; Read P; Dore GJ; Hajarizadeh B
Clin Infect Dis; 2021 Jul; 73(1):e107-e118. PubMed ID: 32447375
[TBL] [Abstract][Full Text] [Related]
8. A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study.
Conway A; Valerio H; Alavi M; Silk D; Treloar C; Hajarizadeh B; Marshall AD; Martinello M; Milat A; Dunlop A; Murray C; Prain B; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Christmass M; Wade A; Montebello M; Dore GJ; Grebely J;
Viruses; 2022 Jul; 14(7):. PubMed ID: 35891535
[TBL] [Abstract][Full Text] [Related]
9. Incidence of primary hepatitis C virus infection among people who inject drugs in Australia pre- and post-unrestricted availability of direct acting antiviral therapies.
Iversen J; Wand H; McManus H; Dore GJ; Maher L
Addiction; 2023 May; 118(5):901-911. PubMed ID: 36524842
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ;
J Viral Hepat; 2020 Mar; 27(3):281-293. PubMed ID: 31698545
[TBL] [Abstract][Full Text] [Related]
11. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
[TBL] [Abstract][Full Text] [Related]
12. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data.
Palmateer NE; McAuley A; Dillon JF; McDonald S; Yeung A; Smith S; Barclay S; Hayes P; Shepherd SJ; Gunson RN; Goldberg DJ; Hickman M; Hutchinson SJ
Addiction; 2021 Oct; 116(10):2893-2907. PubMed ID: 33651446
[TBL] [Abstract][Full Text] [Related]
13. The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia.
Butler K; Day C; Dietze P; Bruno R; Alati R; Burns L
J Subst Abuse Treat; 2015 Nov; 58():90-4. PubMed ID: 26117080
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study.
Malme KB; Ulstein K; Finbråten AK; Wüsthoff LEC; Kielland KB; Hauge J; Dalgard O; Midgard H
Int J Drug Policy; 2023 Jun; 116():104044. PubMed ID: 37149914
[TBL] [Abstract][Full Text] [Related]
15. Is hepatitis C virus (HCV) elimination achievable among people who inject drugs in Tijuana, Mexico? A modeling analysis.
Marquez LK; Cepeda JA; Bórquez A; Strathdee SA; Gonzalez-Zúñiga PE; Fleiz C; Rafful C; Garfein RS; Kiene SM; Brodine S; Martin NK
Int J Drug Policy; 2021 Feb; 88():102710. PubMed ID: 32165050
[TBL] [Abstract][Full Text] [Related]
16. Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017.
Aas CF; Vold JH; Skurtveit S; Odsbu I; Chalabianloo F; Lim AG; Johansson KA; Fadnes LT
Subst Abuse Treat Prev Policy; 2020 Jun; 15(1):44. PubMed ID: 32605625
[TBL] [Abstract][Full Text] [Related]
17. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study.
Alavi M; Grebely J; Micallef M; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ;
Clin Infect Dis; 2013 Aug; 57 Suppl 2():S62-9. PubMed ID: 23884068
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system.
Gibbs D; Price O; Grebely J; Larney S; Sutherland R; Read P; Butler K; Degenhardt L; Peacock A
Drug Alcohol Depend; 2021 Nov; 228():109050. PubMed ID: 34607193
[TBL] [Abstract][Full Text] [Related]
19. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L
J Hepatol; 2019 Jan; 70(1):33-39. PubMed ID: 30367897
[TBL] [Abstract][Full Text] [Related]
20. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial.
Akiyama MJ; Norton BL; Arnsten JH; Agyemang L; Heo M; Litwin AH
Ann Intern Med; 2019 May; 170(9):594-603. PubMed ID: 30959528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
